Employees: 1,522
Size Shin Nippon Biomedical Laboratories (2395.T) is a Japan Industrials company (Miscellaneous Commercial Services) with a market value of $297M, the 1362nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,157 on 18 Nov 2026.
Performance Over six months the shares fell 5.2%, against -27.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +5.5%); the operating margin is 11.8% (peer median -0.2%).
Valuation It trades at 11.5× forward earnings against a peer median of 15.5× (5th cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.5 points below its cost of capital (5.0% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥35.3B | ¥32.5B | ¥32.4B | ¥26.5B | ¥25.1B |
| Revenue growth | — | 0% | +23% | +5% | — |
| Gross profit | ¥18.3B | ¥15.8B | ¥16.6B | ¥14.0B | ¥12.8B |
| EBITDA | ¥7.70B | ¥6.09B | ¥5.60B | ¥6.03B | ¥6.85B |
| Net income | ¥5.70B | ¥4.57B | ¥4.92B | ¥5.53B | ¥6.06B |
| Free cash flow | n/a | ¥3.15B | -¥3.82B | -¥6.48B | -¥836M |
| Capital expenditure | n/a | ¥5.34B | ¥10.9B | ¥8.61B | ¥4.96B |
| Total debt | ¥48.8B | ¥41.4B | ¥34.6B | ¥26.3B | ¥18.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2395.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.9% | -5.5% | 2nd lowest of 21 |
| 6-month return | -5.2% | -27.2% | 6th highest of 21 |
| Distance from 52-week high | -42.3% | -43.1% | 11th highest of 21 |
| Revenue growth (TTM) | +1.9% | +5.5% | 9th lowest of 21 |
| Operating margin | 11.8% | -0.2% | 6th highest of 21 |
| Forward P/E | 11.5× | 15.5× | 5th cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 2.8% | 4.9% | 5th least demanding of 11 |
| Growth delivered (Del g) | +16.6% | +13.5% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -13.8 pp | -10.4 pp | 5th least demanding of 11 |
| ROIC minus cost of capital | -0.5 pp | -7.1 pp | 8th highest of 21 |
| EV / EBITDA | 9.4× | 8.5× | 5th most expensive of 12 |
| Net debt / EBITDA | 3.2× | -0.7× | most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shin Nippon Biomedical Laboratories 2395.T | Japan | $297M | -5% | +2% | 12% | 11.5× | 2.8% | +16.6% |
| Beijing ZEHO Waterfront Ecological Environment Treatment 605069.SS | China | $296M | -42% | +3% | -62% | n/a | n/a | n/a |
| Qingdao Richmat Intelligence Technology 301320.SZ | China | $295M | -35% | +20% | -3% | n/a | n/a | n/a |
| Wuhan Nusun Landscape 300536.SZ | China | $300M | -48% | +154% | -57% | n/a | n/a | n/a |
| Jiangsu Recbio Technology 2179.HK | Hong Kong | $302M | -39% | -82% | -25,868% | n/a | n/a | n/a |
| Guangzhou S.P.I Design 300844.SZ | China | $291M | -33% | -4% | -12% | n/a | n/a | n/a |
| Corporate Travel Management CTD.AX | Australia | $305M | -76% | +7% | 6% | 17.9× | 9.8% | +30.6% |
| Knowit KNOW.ST | Sweden | $306M | +25% | -6% | 2% | 23.6× | 6.1% | +12.1% |
| Jiayuan Science And Technology 301117.SZ | China | $286M | -64% | -41% | -67% | 20.8× | n/a | n/a |
| Nippon Air Conditioning Services 4658.T | Japan | $309M | -10% | +7% | 7% | n/a | -0.6% | +7.1% |
| FSE Lifestyle Services 0331.HK | Hong Kong | $309M | -2% | -3% | 6% | 3.9× | n/a | n/a |
| Hynar Water 300961.SZ | China | $283M | -24% | +5% | -35% | n/a | 39.1% | -8.0% |
| GMO Financial Gate 4051.T | Japan | $313M | +8% | +26% | 12% | 20.2× | 13.0% | +26.1% |
| Elixirr International ELIX.L | United Kingdom | $314M | -35% | +29% | 21% | 7.3× | 3.8% | +37.6% |
| Rejlers REJL-B.ST | Sweden | $314M | -13% | +6% | 6% | 15.8× | -2.3% | +14.9% |
| Qingdao Greensum Ecology 300948.SZ | China | $318M | -38% | +23% | -39% | n/a | n/a | n/a |
| Palm Eco-Town Development 002431.SZ | China | $319M | -28% | -52% | -50% | n/a | 14.2% | -16.0% |
| Globe-Ing 277A.T | Japan | $323M | -21% | +31% | 34% | 15.2× | -5.0% | +31.2% |
| Omni Bridgeway OBL.AX | Australia | $323M | 0% | +75% | -15% | 8.8× | n/a | n/a |
| Hackett HCKT | United States | $325M | +31% | -8% | 13% | 8.5× | -0.3% | +5.0% |
| ECOPRO HN 383310.KS | South Korea | $325M | -26% | -2% | 13% | 15.5× | n/a | n/a |